JPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

JPMorgan Chase & Co. grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 2,088.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 440,167 shares of the company’s stock after acquiring an additional 420,057 shares during the quarter. JPMorgan Chase & Co. owned 1.15% of Tarsus Pharmaceuticals worth $14,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its holdings in Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares during the last quarter. Creative Planning purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $362,000. Vestal Point Capital LP purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $7,565,000. Essex Investment Management Co. LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $3,590,000. Finally, Verition Fund Management LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter worth $763,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TARS has been the topic of a number of analyst reports. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Trading Down 4.6 %

NASDAQ TARS opened at $52.69 on Friday. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -13.83 and a beta of 1.02. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.14. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The business’s fifty day moving average is $51.02 and its 200-day moving average is $37.57.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.